Page 2 - Alexander Drilon News Today

Foundation Expands its Research Reviewing Body to Meet Strategic Research Investment ObjectiveNEW YORK, June 27, 2022 /PRNewswire/ -- The Lung Can...

/PRNewswire/ -- The Hamoui Foundation and LUNGevity Foundation today announced the 2022 recipients of the first The Hamoui Foundation/LUNGevity Clinical...

Fatigue 17 3 12 2 Lipase increased 17 3 17 2 Anaemia 16 5 2 - Amylase increased 15 1 13 1 Nausea 12 1 7 - Vomiting 12 3 4 - Oedema peripheral 11 - 9 - Abdominal pain 10 2 1 -... | October 7, 2021

Share this article Share this article CAMBRIDGE, Mass., April 10, 2021 /PRNewswire/ -- Nuvalent, Inc., a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced preclinical data supporting advancement of its parallel lead programs in non-small cell lung cancer (NSCLC), including NUV-520 – a potential best-in-class ROS1-selective inhibitor – and NUV-655 – an ALK-selective inhibitor. Data are being presented at the 2021 Ame...

Crizotinib (Xalkori) has approval as first-line therapy for ROS1 fusion-positive metastatic NSCLC but has poor CNS penetration, the authors noted, adding that in about half of patients treated with crizotinib, initial progression occurs only in the CNS. Entrectinib is designed to cross the blood-brain barrier, and preclinical studies showed that the agent achieves high CNS concentrations, which were associated with strong efficacy in brain-tumor models. Integrated Analysis For the analysis, th...

Share Print "When I was running and my legs started to hurt, I reminded myself that my brother has lost a leg to cancer already,” says Sandy Freiberg, pictured. On September 13, Sandy Freiberg ran a marathon to honor his brother, Evan Freiberg, who is in his fifth year of cancer treatment at Memorial Sloan Kettering. Only Sandy didn’t run the race among a pack of people and with great fanfare at the finish line. He ran 26.2 miles entirely on his own. Sandy had signed u...

Share Print Medical oncologist Alexander Drilon is leading the development of new targeted drugs that can control lung cancer better than ever before. Middle school chorus and orchestra teacher Melissa Crouse had lived in the Pittsburgh area her whole life. But on a trip to visit her brother in southwest Florida, she decided on a whim to apply for teaching jobs there. The single mom, then 51, quickly received an offer. “Three big things happened to me at the same time,�...

Share Print Since 2007, Alan and Sandra Gerry have supported MSK in the quest to learn more about cancer metastasis. Alan Gerry has always recognized an opportunity when he sees one. His parents both emigrated from Russia to New York City in their youth so their families could build better lives. They met while working in a garment factory on the Lower East Side and soon married and had three boys. In 1930, when Mr. Gerry was two years old, the family moved two hours nort...

Share Print Ken Manotti is Senior Vice President and Chief Development Officer at Memorial Sloan Kettering. He leads philanthropic fundraising efforts at MSK and has been in the role since 2018. Why did you choose philanthropy as a career? I had no plans to be in this profession. But many years ago, a mentor asked me to help with fundraising at the University of Pennsylvania. She was very patient and taught me how to raise money for good causes. Back to top Is it hard as...